YNIOS PHARMA develops an innovative critical care treatment aimed at increasing patient’s survival rate, protecting from multiple organ failure and complications, and reducing ICU stay length. Clinical development targets Sepsis & Septic Shock, two deadly critical care indications, and optimizes label extensions with other critical care diseases presenting common features, including Acute Ischemic Stroke, Acute Myocardial Infarction, organ transplantation, and Ischemic-Reperfusion Injuries.

On the occasion of World Sepsis Day, September 13, 2025, it is important to remember that nearly 50 million people worldwide are affected by Sepsis each year, including 40% of children under 5 years of age, and 11 million people die from it. Survivors remain at increased risk of death and often suffer extremely disabling social and professional consequences, such as amputations or cognitive impairment.